Skip to main content
Industry News
BioMarin's hemophilia A gene therapy gets RMAT tag
3/11/2021

BioMarin Pharmaceutical's investigational gene therapy for severe hemophilia A Roctavian, or valoctocogene roxaparvovec, was granted regenerative medicine advanced therapy designation by the FDA. The single infusion therapy is delivered directly into the bloodstream to carry the functional gene copy to the liver.

Full Story: